Learn To Invest
Stocks Special Reports LICs Credit Funds ETFs Tools SMSFs
Video Archive Article Archive
News Stocks Special Reports Funds ETFs Features SMSFs Learn
About

News

Top 10 articles of last week

Lex Hall  |  23 Jul 2018Text size  Decrease  Increase  |  
Email to Friend

A 'breakthrough' product trial that could put biotech CSL on the path to $250 a share topped Morningstar's top 10 stories this week alongside news of another strong half-year for the Australian ETF industry.

Blockbuster heart trial could put CSL on track to hit $250

This ASX-listed biotech is working on a "blockbuster" cardiovascular product that has the potential to take its stock price to $250, says Morningstar equity analyst Chris Kallos.

ETFs post half-year records

It's been another strong half year for the Australian exchange-traded funds industry, finishing the first half of 2018 at record highs, according to the BetaShares 2018 Australian ETF Review.

ASX a standout despite high price

This Australian financial services company may be expensive at its current price but it has a solid reputation, good profit margins and significant competitive advantages, according to Morningstar analysis.

Investing Compass
Listen to Morningstar Australia's Investing Compass podcast
Take a deep dive into investing concepts, with practical explanations to help you invest confidently.
Investing Compass

Falling short: Aussies underestimate the cost of retirement

Australians are underestimating by up to 20 per cent the amount of money they’ll need in retirement, according to a new survey from global investment manager Schroders.  

Viva Energy IPO a high-octane opportunity, says Morningstar

The float of Viva Energy is a high-octane opportunity despite the threat of electric vehicles and increased competition, Morningstar says.

Super funds post another stellar year

Australian super funds are closing in on a decade of positive returns as the median growth fund ends the year up by 9.2 per cent, according to a report by superannuation research house Chant West. 

Aussie investors putting too many eggs in the local basket

When it comes to diversification, the 11 million Australians holding investments outside of their superannuation fund still tend to place all their eggs in one basket.

Investing is easy, adjusting behaviour is not

Being aware of individual behavioural biases is a vital part of the investment process, according to Daniel Kahneman, Nobel laureate and author of Thinking, Fast and Slow.

Ramsay remains undervalued despite failed acquisition bid

Morningstar analysts have maintained their fair value estimate for global hospital group Ramsay Health Care (ASX: RHC) after its French subsidiary made an unsuccessful bid to acquire pan-European healthcare service provider Capio.

Westpac puts brakes on SMSF property lending

SMSF trustees looking to invest their savings in the property market have suffered another blow following the move by the nation's second largest mortgage lender to withdraw new loan offers.

  

More from Morningstar

10 discount China-Hong Kong stocks as trade war bites

Investing basics: how to buy shares on the ASX

Make better investment decisions with Morningstar Premium | Free 4-week trial

 

Lex Hall is a Morningstar content editor, based in Sydney.

© 2018 Morningstar, Inc. All rights reserved. Neither Morningstar, its affiliates, nor the content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. This information is to be used for personal, non-commercial purposes only. No reproduction is permitted without the prior written consent of Morningstar. Any general advice or 'class service' have been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892), or its Authorised Representatives, and/or Morningstar Research Ltd, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. Please refer to our Financial Services Guide (FSG) for more information at www.morningstar.com.au/s/fsg.pdf. Our publications, ratings and products should be viewed as an additional investment resource, not as your sole source of information. Past performance does not necessarily indicate a financial product's future performance. To obtain advice tailored to your situation, contact a licensed financial adviser. Some material is copyright and published under licence from ASX Operations Pty Ltd ACN 004 523 782 ("ASXO"). The article is current as at date of publication.

is senior editor for Morningstar Australia

© 2021 Morningstar, Inc. All rights reserved. Neither Morningstar, its affiliates, nor the content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. This information is to be used for personal, non-commercial purposes only. No reproduction is permitted without the prior written consent of Morningstar. Any general advice or 'regulated financial advice' under New Zealand law has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892), or its Authorised Representatives, and/or Morningstar Research Ltd, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. For more information, refer to our Financial Services Guide (AU) and Financial Advice Provider Disclosure Statement (NZ). Our publications, ratings and products should be viewed as an additional investment resource, not as your sole source of information. Morningstar’s full research reports are the source of any Morningstar Ratings and are available from Morningstar or your adviser. Past performance does not necessarily indicate a financial product's future performance. To obtain advice tailored to your situation, contact a licensed financial adviser. Some material is copyright and published under licence from ASX Operations Pty Ltd ACN 004 523 782. The article is current as at date of publication.

Email To Friend